Pascal, congratulations acquiring Anadys, any update on Oxigene?
I know you guys know best but Novartis could at any day now surprise you and offer to buy Zybrestat and their VDA patent portfolio.
As we know, once Oxigene presents it will be too obvious that zybrestat is the blockbuster for destroying cancerous tumors, not to mention its other applications. Since Novartis and Astra know zybrestat's molecular structure is superior, hence the prolonged survival after 12 months now, what's to stop them from beating you to the table?
So if Roche waits any longer they risk the stock soaring on the data as the market realizes zybrestat is the most efficacious of all the agents that were determined years ago.
Just my thoughts.
Again, great job acquiring Anadys; with Setrobuvir the Hep C market is now yours!
they're considering Catalyst Pharmaceutical Partners for addressing the drug addiction market. The company's stock symbol is CPRX and trades around $1.00 per share. Dendreon Corp's former genius exec recently joined Catalyst too.